Triple combination therapy trial for HR+/HER2- breast cancer halts early due to toxic

[News]

HR+/HER2- breast cancer constitutes approximately 65?75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.

More... (https://www.news-medical.net/news/20260928/Triple-combination-therapy-trial-for-HR2bHER2e28892-breast-cancer-halts-early-due-to-toxicity-concerns.aspx)